Angion to Participate in Upcoming September Investment Conferences
September 02, 2021 00:20 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion Provides Corporate Update and Reports Second Quarter 2021 Financial Results
August 12, 2021 16:05 ET
|
Angion Biomedica Corp.
-- Topline data in ANG-3777 Phase 3 study now expected to be announced in early Q4 rather than at year end -- Phase 1 data demonstrated ANG-3070 was well-tolerated across dose cohorts, achieving drug...
Acute Kidney Injury Treatment Market Report to 2031: Visiongain Research Inc.
July 27, 2021 10:43 ET
|
Visiongain Ltd
Visiongain has published a new report on Acute Kidney Injury Treatment Market Report up to 2031: Forecasts By Product (Dialysis (Intermittent Hemodialysis, Continuous Renal Replacement Therapy (CRRT),...
Angion Provides Corporate Update and Reports First Quarter 2021 Financial Results
May 17, 2021 07:00 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y., May 17, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel...
Angion and Vifor Pharma Announce Completion of Enrollment in Phase 2 Study of ANG-3777 for Cardiac-Surgery Associated Acute Kidney Injury
April 29, 2021 00:05 ET
|
Angion Biomedica Corp.
UNIONDALE, N.Y. and ST. GALLEN, Switzerland, April 29, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp (NASDAQ:ANGN) and Vifor Pharma today announced completion of enrollment for Angion’s AKI-002-15...
Peter Lougheed Centre Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
February 26, 2021 08:42 ET
|
Arch Biopartners
TORONTO, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the Peter Lougheed Center (PLC) in Calgary,...
University of Calgary Joins the Phase II Trial of LSALT Peptide for the Treatment of Complications in Hospitalized COVID-19 Patients
January 05, 2021 07:50 ET
|
Arch Biopartners
TORONTO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that the University of Calgary Cumming School of...
Healthmap Solutions Urges Medicare Advantage Plans to Act Now In Advance of 21st Century Cures Act Implementation
July 22, 2020 09:00 ET
|
Healthmap Solutions
TAMPA, Fla., July 22, 2020 (GLOBE NEWSWIRE) -- Healthmap Solutions, a rapidly growing specialty Population Health Management (PHM) company with a flagship Kidney Health Management (KHM) program,...
Arch Biopartners Closes Non-Brokered Private Placement
June 30, 2020 09:21 ET
|
Arch Biopartners
TORONTO, June 30, 2020 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating...
FDA Grants Arch Biopartners Permission to Proceed with Phase II trial to Evaluate Metablok (LSALT peptide) for the Treatment of COVID-19 patients
June 16, 2020 10:48 ET
|
Arch Biopartners
International, multi-center, randomized, double-blind, placebo-controlled clinical study targeting the prevention of Acute Respiratory Distress Syndrome (ARDS) and Acute Kidney Injury (AKI) in...